Coronavirus Update: BIO Facilitates COVID-19 Collaborations, ASCO Goes Virtual
BIO hosts summit to support collaborations on coronavirus vaccines and therapeutics, Vir advances COVID-19 antibody candidates, Gilead renounces orphan status for remdesivir, BMS joins Pfizer in pushing back investor meeting, and ASCO goes virtual.
You may also be interested in...
Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.